The Most Unlucky Biotech in the Worldhttp://www.fool.com/investing/general/2013/06/21/idenix-idix-needs-more-data.aspx Brian Orelli
June 21, 2013
Idenix Pharmaceuticals (NASDAQ: IDIX) just can't catch a break. The company is down nearly 30% today after announcing that the Food and Drug Administration won't let Idenix start a clinical trial for its hepatitis C drug IDX20963 until the company turns in additional preclinical safety data.
This isn't the first time, or even the second or third time, that the FDA has delayed Idenix's clinical trials.
Last year, two of Idenix's hepatitis C drugs, IDX184 and IDX19368, were put on clinical hold by the FDA because they had a structure related to Bristol-Myers Squibb's (NYSE: BMY) BMS-986094, which produced severe cardiac side effects in its clinical trial. Like Bristol-Myers, Idenix eventually scrapped development of the drugs.
And back in 2010, IDX184 and another compound, IDX320, were put on a clinical hold, which Idenix eventually got lifted for IDX184 after concluding that IDX320 was the problem child.
Don't forget safety
But that confidence can cause investors to forget about the other reason the FDA requires clinical trials: safety. A severe adverse event that happens in 1% of patients might not show up in a small 30-patient trial.
What's the issue?